COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Dose Escalating Study to Assess the Safety and Tolerability of GT-001

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03490786
Recruitment Status : Completed
First Posted : April 6, 2018
Last Update Posted : April 6, 2018
Information provided by (Responsible Party):
Gila Therapeutics, Inc.

Brief Summary:
Dose escalation study of GT-001

Condition or disease Intervention/treatment Phase
Feeding and Eating Disorders Drug: GT-001 Phase 1

Detailed Description:
This is a dose-escalation design trial. Twelve evaluable subjects (n=12) with BMIs of 30 to 40 kg/m2 will receive a single dose of placebo followed by study drug applied directly to the surface of the tongue mucosa with a disposable pipette followed by a one-day washout. A total of seven (7) doses will escalate to a dose of 2.5 mg.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Intervention Model: Single Group Assignment
Intervention Model Description: dose escalation
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Dose Escalating Study to Assess the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of a Lingual Application of GT-001 in Subjects With Obesity.
Actual Study Start Date : July 16, 2017
Actual Primary Completion Date : August 9, 2017
Actual Study Completion Date : October 2, 2017

Arm Intervention/treatment
Experimental: Dose escalation
Single arm dose escalation.
Drug: GT-001
PK, PD Study to Determine Safety of Escalating Doses of GT-001
Other Names:
  • PYY(3-36)
  • Peptide YY (3-36)

Primary Outcome Measures :
  1. Demonstrate safe doses of PGT-001 for reduction of body weight in obese volunteers. [ Time Frame: approximately two weeks ]
    Measures of the safety and tolerability of GT-001 include documentation of adverse events and changes (compared to baseline) in vital signs, physical examination, and laboratory tests.

Secondary Outcome Measures :
  1. Dose-relationship of adverse events [ Time Frame: approximately two weeks ]
    Incidence, severity and dose-relationship of adverse events as well as changes in physical examinations, vital signs and/or laboratory evaluations as a measure of safety and tolerability.

  2. Dose relationship to peak plasma concentration of GT-001 [ Time Frame: Approximately two weeks ]
    Peak plasma concentration of GT-001 to assess relationship to dose of GT-001.

  3. Dose relationship to hunger and satiety [ Time Frame: approximately two weeks ]
    Measurement of hunger and satiety will be conducted using visual analog scores to assess a relationship to dose of GT-001

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Adult participants with obesity class I and II (BMI 30-40 kg/m2)
  • Willing and able to provide written informed consent after reviewing the design and risks of the study and prior to completing any study-related procedure
  • Willing and able to understand and comply with all study procedures and requirements.
  • Women must have a predictable menstrual cycle and taking either monophasic oral contraceptives, or transdermal (Ortho Evra and Evra) at least one month prior to the study.
  • Alternatively, post-menopausal women (defined as period of spontaneous amenorrhea for more than 1 year), and bilateral oophorectomized women are allowed into the study.
  • Must be able to complete the Weight Efficacy Life-Style Questionnaire (WEL).
  • Systolic blood pressure 100-160 mmHg at the time of screening.
  • Stable and compliant treatment with oral medications for at least 4 weeks prior to screening.
  • Women of child bearing potential (WOCBP) and males must agree to use at least two forms of contraception, of which one includes a barrier method (male condom) by the male partner, during study participation and continued for at least 90 days after the conclusion of the final dose.
  • In addition, sperm donations by male subjects are not permitted during the subject's participation in the research study and for at least 90 days after the conclusion of the final dose. This criterion may be waived for male subjects who have undergone a vasectomy at least 6 months prior to screening.
  • Willing and able to abstain from drugs, , and tobacco during study participation.
  • Must have abstained from alcohol use for 48 hours prior to study day 1 through the duration of the study
  • Must have abstained from any tobacco- or nicotine-containing products (e.g., cigarettes, e-cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to study day 1.
  • History of stable weight for at least 3 months prior to study entry.

Exclusion Criteria:

  • Known hypersensitivity or allergy to Peptide YY, Pancreatic polypeptide (PP), other similar polypeptides or related compounds
  • Known mutation to PYY or Y2 receptor gene (i.e., Pima Indians)
  • Any medical condition for which modification of the medication that cannot be performed either safely or feasibly. Chronic diseases including metabolic, psychiatric, cardiovascular, endocrine, etc. for which the participant is not stable for 60 days prior to study initiation
  • Female subjects who are pregnant or breast-feeding
  • Female subjects of child bearing potential who are not on oral contraceptives or using biphasic or triphasic oral contraceptives
  • Post-menopausal women who have not had a period of spontaneous amenorrhea for more than 1 year Unstable psychological or behavior profile (e.g., anxiety, depression)
  • Subjects with fasting glucose levels greater than 125 mg/dl.
  • Type I or Type II diabetes
  • Poor dentition or oral pathology
  • Unable or unwilling to give written informed consent.
  • Temperature > 38°C (oral or equivalent)
  • Sepsis or active infection requiring IV antimicrobial treatment
  • Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy (not including restrictive mitral filling patterns)
  • Major neurologic event, including cerebrovascular events within 60 days prior to study initiation
  • Significant pulmonary disease (e.g., history of oral daily steroid dependency, history of CO2 retention or need for intubation for acute exacerbation, or currently receiving IV steroids)
  • Known hepatic impairment as indicated by any of the following:

    • Total bilirubin > 3 mg/dl
    • Albumin < 2.8 mg/dl, with other signs or symptoms of hepatic dysfunction
    • Increased ammonia levels, if performed, with other signs or symptoms of hepatic dysfunction
  • Any organ transplant recipient or currently listed (anticipated in the next 60 days) for transplant
  • Major surgery within 30 days prior to study initiation
  • Positive screen for Hepatitis B (HbsAg, Hepatitis B Surface Antigen), Hepatitis C (anti-HCV, Hepatitis C Antibody), or HIV (anti-HIV 1/2)
  • Received an investigational intervention within 30 days prior to study initiation, or have received PYY3-36, GLP-1 agonists, insulin or DPP-IV inhibitors in a previous clinical trial.
  • Consumption of alcohol within 48 hours prior to study day1 and through study day 15 or early termination
  • Use of any tobacco- or nicotine-containing products (e.g., cigarettes, e-cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months
  • A positive urine drug screen for ethanol, cotinine, cocaine, THC, barbiturates, amphetamines, benzodiazepines, and/or opiates
  • A history of difficulty with donating blood, or having donated blood or blood products within 45 days prior to study initiation
  • Use of weight loss drugs Orlistat (Alli or Xenical), Qsymia, Phentermine, Contrave, Lorcaserin, liraglutide, topiramate or exenatide within the last six months.
  • Concurrent use of antihistamines
  • Any condition that, in the opinion of the Investigator or Medical Monitor, would render the subject unsuitable for participation in the study
  • Unable to consume the test meal

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03490786

Layout table for location information
United States, California
Orange County Research Center
Tustin, California, United States, 92780
Sponsors and Collaborators
Gila Therapeutics, Inc.

Layout table for additonal information
Responsible Party: Gila Therapeutics, Inc. Identifier: NCT03490786    
Other Study ID Numbers: 001
First Posted: April 6, 2018    Key Record Dates
Last Update Posted: April 6, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Gila Therapeutics, Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Feeding and Eating Disorders
Mental Disorders